Top-News
Biotechnologie Dänemark

Novo-Nordisk News

Aktie
WKN:  A3EU6F ISIN:  DK0062498333 US-Symbol:  NONOF
133,34 €
-0,42 €
-0,31%
13:09:03 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
3,48 Mrd.
Marktkapitalisierung *
468,13 Mrd. €
Streubesitz
70,75%
Index-Zugehörigkeit
Stoxx Europe 50
IR-Website
zur Website
*Stand: 13.09.2023
Weiter abwärts? Short handeln - Jetzt mit Hebel 9,48: VM9PJ5
Werbung

Unternehmensmeldungen

24.06.24 - GlobeNewswire
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline
In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of ...
18.06.24 - GlobeNewswire
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
FLOW kidney outcomes trial data evaluating efficacy and safety of once-​weekly semaglutide 1.0 mg in people with type 2 diabetes 1 SELECT cardiovascular outcomes trial data ...
25.03.24 - GlobeNewswire
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
Bagsværd, Denmark, and Han n over, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for ...
31.01.24 - GlobeNewswire
Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 31 January 2024 – Novo Nordisk A/S has filed its Annual Report 2023 on Form 20-F for the financial year 2023 with the US Securities and Exchange ...
04.01.24 - GlobeNewswire
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity management Cellarity collaboration will build ...
23.11.23 - GlobeNewswire
Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France
Bagsværd, Denmark, 23 November 2023 – Novo Nordisk today announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 2023 1 to expand the ...
10.11.23 - GlobeNewswire
Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark
Bagsværd, Denmark, 10 November 2023 – Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 2023 1 to expand existing manufacturing ...
10.08.23 - GlobeNewswire
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
Bagsværd, Denmark and Montreal, Canada, 1 0 August 2023 – Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up ...
12.06.23 - GlobeNewswire
Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in Hillerød, Denmark
Bagsværd , Denmark, 12 June 2023 - Novo Nordisk today announced plans to invest 15.9 billion Danish kroner starting in 2023 1 to expand an existing Active Pharmaceutical ...
05.06.23 - GlobeNewswire
Novo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining shares
Novo Nordisk has entered into exclusive negotiations with BIO JAG, BIOCORP’s main shareholder, for the purchase of its entire stake in BIOCORP, representing 45.3 % of its share ...
24.05.23 - GlobeNewswire
Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases
Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250- 335 million US dollars for each of seven development programmes , as well as ...
12.04.23 - GlobeNewswire
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and ...
02.03.23 - GlobeNewswire
Novo Nordisk to expand R&D presence in greater Boston area
Bagsværd, Denmark, 2 March 2023 – Novo Nordisk just announced plans to expand its research and development (R&D) presence in the greater Boston metro area, creating one of ...
10.02.23 - GlobeNewswire
Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 – a cell therapy designed to restore heart function in people with advanced heart failure
HS-001 consist s of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs) .
01.02.23 - GlobeNewswire
Novo Nordisk files annual report with the SEC
Bagsværd , Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022 on Form 20-F for the financial year 2022 with the US Securities and Exchange ...
22.11.22 - GlobeNewswire
Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark
Bagsværd , Denmark, 22 November 2022 – Novo Nordisk today announced plans to invest 5.4 bn Danish kroner in the expansion of existing facilities in Bagsværd. The plans also ...
14.10.22 - GlobeNewswire
Novo Nordisk announces the completion of the Forma Therapeutics acquisition
Bagsværd, Denmark, 14 October 2022 – Novo Nordisk today announced that the acquisition of Forma Therapeutics Holdings, Inc. (Forma), announced on 1 September 2022, has ...
12.09.22 - GlobeNewswire
Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence
Bagsværd, Denmark and Redmond , W A , US , 12 September 2022 – Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational ...
01.09.22 - GlobeNewswire
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
Bagsværd, Denmark and Watertown, M ass, US , 01 September 2022 – Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have ...
26.06.21 - GlobeNewswire
Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial
Bagsv æ rd , Denmark, 26 June 2021 – Novo Nordisk today presented data showing that an investigational 2.0 mg dose of Ozempic ® (semaglutide) provided statistically significant ...

Newssuche

Videos

27.06.24 -3,89%
Technical Trading: 10yr T-Notes Long Chance
10yr T-Notes Long Typ: Turbo Open End WKN: JL04UJ Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »